MX390653B - Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. - Google Patents

Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.

Info

Publication number
MX390653B
MX390653B MX2018002447A MX2018002447A MX390653B MX 390653 B MX390653 B MX 390653B MX 2018002447 A MX2018002447 A MX 2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A MX 390653 B MX390653 B MX 390653B
Authority
MX
Mexico
Prior art keywords
antibodies
nephritis
lupusic
treatment
therapeutic
Prior art date
Application number
MX2018002447A
Other languages
English (en)
Spanish (es)
Other versions
MX2018002447A (es
Inventor
Gerald Henry Nabozny
Juergen STEFFGEN
Meera RAMANUJAM
Paul Scholl
Scott Ronald Brodeur
Thomas B Freeman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018002447A publication Critical patent/MX2018002447A/es
Publication of MX390653B publication Critical patent/MX390653B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018002447A 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. MX390653B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
MX2018002447A MX2018002447A (es) 2018-06-15
MX390653B true MX390653B (es) 2025-03-21

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002447A MX390653B (es) 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.

Country Status (16)

Country Link
US (3) US20170058038A1 (enExample)
EP (1) EP3344655B1 (enExample)
JP (2) JP2018529661A (enExample)
KR (1) KR20180039172A (enExample)
CN (1) CN107922501A (enExample)
AU (1) AU2016317028B2 (enExample)
BR (1) BR112018001907A2 (enExample)
CA (1) CA2993996A1 (enExample)
CL (1) CL2018000317A1 (enExample)
DK (1) DK3344655T5 (enExample)
ES (1) ES2969968T3 (enExample)
HU (1) HUE063528T2 (enExample)
MX (1) MX390653B (enExample)
PH (1) PH12018500445B1 (enExample)
PL (1) PL3344655T3 (enExample)
WO (1) WO2017040566A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2019013132A (es) * 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
RU2006141632A (ru) * 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
SMP200800064B (it) * 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP2796467B1 (en) * 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
KR102037432B1 (ko) * 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
PH12018500445A1 (en) 2018-09-10
JP2021185169A (ja) 2021-12-09
ES2969968T3 (es) 2024-05-23
EP3344655A1 (en) 2018-07-11
US20170058038A1 (en) 2017-03-02
JP2018529661A (ja) 2018-10-11
AU2016317028A1 (en) 2018-02-22
DK3344655T5 (da) 2024-10-07
AU2016317028B2 (en) 2021-09-09
PH12018500445B1 (en) 2022-08-10
US20230265203A1 (en) 2023-08-24
EP3344655B1 (en) 2023-07-26
KR20180039172A (ko) 2018-04-17
WO2017040566A1 (en) 2017-03-09
CL2018000317A1 (es) 2018-07-20
BR112018001907A2 (pt) 2018-09-25
PL3344655T3 (pl) 2024-02-19
HUE063528T2 (hu) 2024-01-28
MX2018002447A (es) 2018-06-15
US20190177420A1 (en) 2019-06-13
CA2993996A1 (en) 2017-03-09
CN107922501A (zh) 2018-04-17
DK3344655T3 (da) 2023-10-09

Similar Documents

Publication Publication Date Title
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201691541A1 (ru) Новые анти-baff антитела
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12018500445B1 (en) Use of anti-cd40 antibodies for treatment of lupus nephritis
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201691521A1 (ru) Антитела к интерлейкину-21
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX394051B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo
PH12019502694A1 (en) Anti-trkb antibodies
DK3638293T3 (da) Sammensætninger til behandling af cancer
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201691896A1 (ru) Соединения и способы их применения
BR112018074231A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
EA201792380A1 (ru) Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита